Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium sulfate + magnesium sulfate + potassium chloride is an osmotic laxative combination primarily indicated for cleansing the colon in adults prior to a colonoscopy. Developed by Braintree Laboratories and marketed under the brand name Sutab, this formulation consists of sulfate-based salts that are poorly absorbed by the gastrointestinal tract. These salts create an osmotic gradient that draws water into the intestinal lumen, increasing intraluminal pressure and stimulating peristalsis to facilitate the evacuation of colonic contents. Unlike many other bowel preparations that are administered as large volumes of liquid, this combination is delivered in a tablet format, which may improve patient adherence and tolerability. The inclusion of potassium chloride and magnesium sulfate helps to maintain electrolyte balance during the purgative process.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium sulfate + magnesium sulfate + potassium chloride.